Profound Medical presents TULSA-PRO data

Profound Medical

Twelve-month data from Profound Medical’s (TSXV:PRN) Phase 1 clinical trial of its TULSA-PRO medical device were presented at the European Symposium on Focused Ultrasound Therapy in London.

TULSA is a minimally invasive technology to ablate normal and cancerous prostate tissue, which combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop temperature feedback control.

The primary endpoints of the Phase 1 clinical trial at 12-month follow-up were met, and results support the objectives of conservative whole-gland prostate ablation.

An upcoming pivotal clinical trial will aim to eliminate the safety margin and completely ablate the prostate to the capsule, measuring oncological outcomes while maintaining a similar well-tolerated safety profile.

“The prospective Phase 1 study demonstrated clinical safety and precision of TULSA-PRO for whole-gland prostate ablation, with low toxicity and a well-tolerated safety profile,” CEO, Steve Plymale, said in a statement.

“We are pleased to be moving on to our next milestone of a larger multi-jurisdictional study of 110 patients at 10 clinical trial sites in 2016,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.